PT-141 (HA) 10mg

Description:

PT-141 has been primarily studied for its potential effects on sexual dysfunction and arousal. It works by activating melanocortin receptors in the brain, specifically targeting the melanocortin receptor 4 (MC4R) and melanocortin receptor 3 (MC3R). Activation of these receptors can lead to increased sexual excitement, improved sexual desire, and arousal in both men and women. This mechanism of action makes PT-141 distinct from other medications used to treat sexual dysfunction, such as phosphodiesterase inhibitors like Viagra, which primarily target blood flow.

PT-141 (HA) Research:

Research on PT-141, also known as Bremelanotide, has primarily focused on its effects on sexual dysfunction and arousal in both men and women. Here are some key findings from clinical studies:

Erectile Dysfunction (Men):

• Studies have shown that PT-141 can induce penile erection in men with erectile dysfunction. It works by increasing blood flow to the genital area, leading to improved erectile function.
• In a phase 2b clinical trial involving men with mild to moderate erectile dysfunction, PT-141 was found to be more effective than a placebo in improving erectile function.
• Another study demonstrated that PT-141 produced significant improvements in erectile function, sexual satisfaction, and sexual desire in men with erectile dysfunction who were non-responsive to phosphodiesterase-5 inhibitors (such as Viagra).

Sexual Dysfunction (Female):

• Clinical trials have shown that PT-141 can increase sexual desire and improve sexual satisfaction in women with hypoactive sexual desire disorder (HSDD) or other forms of female sexual dysfunction.
• In a phase 3 clinical trial involving premenopausal women with HSDD, PT-141 demonstrated significant improvements in sexual desire and related distress compared to a placebo.
• Other studies have also reported positive effects of PT-141 on sexual desire, arousal, and satisfaction in women

In a clinical trial published in The Journal of Sexual Medicine in 2013 (Palatin Technologies, Inc.), researchers investigated the use of PT-141 in premenopausal women with female sexual dysfunction. The study found that PT-141, when self-administered as a subcutaneous injection, was associated with increased sexual desire and improved sexual function compared to a placebo. The treatment was generally well tolerated, with the most common side effects being mild-to-moderate nausea and flushing.

Certificate of Analysis (COA) and High Performance Liquid Chromatography (HPLC)